当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.

Abstract：

:The introduction of BCR-ABL tyrosine kinase inhibitors has revolutionized the treatment of chronic myeloid leukemia (CML). A major clinical aim remains the identification and elimination of low-level disease persistence, termed "minimal residual disease". The phenomenon of disease persistence suggests that despite targeted therapeutic approaches, BCR-ABL-independent mechanisms exist which sustain the survival of leukemic stem cells (LSCs). Although other markers of a primitive CML LSC population have been identified in the preclinical setting, only CD26 appears to offer clinical utility. Here we demonstrate consistent and selective expression of CD93 on a lin-CD34+CD38-CD90+ CML LSC population and show in vitro and in vivo data to suggest increased stem cell characteristics, as well as robust engraftment in patient-derived xenograft models in comparison with a CD93- CML stem/progenitor cell population, which fails to engraft. Through bulk and single-cell analyses of selected stem cell and cell survival-specific genes, we confirmed the quiescent character and demonstrate their persistence in a population of CML patient samples who demonstrate molecular relapse on TKI withdrawal. Taken together, our results identify that CD93 is consistently and selectively expressed on a lin-CD34+CD38-CD90+ CML LSC population with stem cell characteristics and may be an important indicator in determining poor TKI responders.

journal_name

Leukemia

journal_title

Leukemia

authors

Kinstrie R,Horne GA,Morrison H,Irvine D,Munje C,Castañeda EG,Moka HA,Dunn K,Cassels JE,Parry N,Clarke CJ,Scott MT,Clark RE,Holyoake TL,Wheadon H,Copland M

doi

10.1038/s41375-019-0684-5

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

1613-1625

issue

6

eissn

0887-6924

issn

1476-5551

pii

10.1038/s41375-019-0684-5

journal_volume

34

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Variant translocation t(3;15)(q21;q22) in a patient with acute promyelocytic leukemia.

    abstract：:Bone marrow cells from most patients with acute promyelocytic leukemia contain a highly specific cytogenetic rearrangement, a reciprocal translocation between the long arms of chromosomes 15 and 17. Several cases of variant translocations involving 17q but not 15q have been reported, leading to the suggestion that the...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Heim S,Kristoffersson U,Mandahl N,Malm C,Mitelman F

    更新日期：1988-01-01 00:00:00

  • Management of infective complications in patients with advanced hematologic malignancies in home care.

    abstract：:A home care service has been implemented at our center with the aim of offering domiciliary assistance to patients with hematologic malignancies in advanced phase. We report our experience concerning the home management of these patients in the setting of infective complications. Of 151 patients in home care, 70 (46%)...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400851

    authors： Girmenia C,Moleti ML,Cartoni C,Cedrone M,De Gregoris C,De Sanctis V,Giovannini M,Latagliata R,Niscola P,Romani C,Rondinelli MB,Tosti S,Mandelli F

    更新日期：1997-11-01 00:00:00

  • Translocation t(9;11)(p21;q23) in pediatric de novo and secondary acute myeloblastic leukemia.

    abstract：:The t(9;11)(p21;q23) has been associated with characteristic clinical features and a superior treatment outcome in previously untreated pediatric acute myeloblastic leukemia (AML), but has not been well studied in children with secondary AML. This translocation was detected in 6.7% of de novo and 46% of secondary AML ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Sandoval C,Head DR,Mirro J Jr,Behm FG,Ayers GD,Raimondi SC

    更新日期：1992-06-01 00:00:00

  • Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

    abstract：:Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the effic...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2009.111

    authors： Giles FJ,O'Dwyer M,Swords R

    更新日期：2009-10-01 00:00:00

  • Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL.

    abstract：:In B-CLL IgV(H) genes mutational status is a major prognostic factor. Since sequencing of IgV(H) genes is not available in most laboratories, an easily performed surrogate assay is desirable. To identify the best surrogate assay, and to better discriminate prognostic subgroups we analyzed clinical and biological data ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402780

    authors： Magnac C,Porcher R,Davi F,Nataf J,Payelle-Brogard B,Tang RP,Oppezzo P,Lévy V,Dighiero G,Ajchenbaum-Cymbalista F

    更新日期：2003-01-01 00:00:00

  • LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.

    abstract：:The predominant usage of VH4-34 and V3-21 and reports of stereotyped CDR3s suggest a shared antigenic target of B-cell receptors (BCR) from mantle cell lymphomas (MCL). To identify the target antigens of MCL-BCRs, BCRs from 21 patients and seven MCL cell lines were recombinantly expressed and used for antigen screenin...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0182-1

    authors： Thurner L,Hartmann S,Fadle N,Kemele M,Bock T,Bewarder M,Regitz E,Neumann F,Nimmesgern A,von Müller L,Pott C,Kim YJ,Bohle RM,Wasik M,Schuster SJ,Hansmann ML,Preuss KD,Pfreundschuh M

    更新日期：2019-01-01 00:00:00

  • Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.

    abstract：:Successful treatment results for MLL-rearranged Acute Lymphoblastic Leukemia (ALL) in infants remain difficult to achieve. Significantly contributing to therapy failure is poor response to glucocorticoids (GCs), like prednisone. Thus, overcoming resistance to these drugs may be a crucial step towards improving prognos...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.245

    authors： Spijkers-Hagelstein JA,Pinhanços SS,Schneider P,Pieters R,Stam RW

    更新日期：2014-04-01 00:00:00

  • Detection of illegitimate rearrangements within the immunoglobulin light chain loci in B cell malignancies using end sequenced probes.

    abstract：:Translocations involving the immunoglobulin loci are recurring events of B cell oncogenesis. The majority of translocations involve the immunoglobulin heavy chain (IGH) locus, while a minor part involves the immunoglobulin light chain loci consisting of the kappa light chain (IGK) located at 2p11.2 and the lambda ligh...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402648

    authors： Poulsen TS,Silahtaroglu AN,Gisselø CG,Tommerup N,Johnsen HE

    更新日期：2002-10-01 00:00:00

  • Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

    abstract：:Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a ...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/leu.2016.299

    authors： Schlenk RF,Stegelmann F,Reiter A,Jost E,Gattermann N,Hebart H,Waller C,Hochhaus A,Platzbecker U,Schafhausen P,Blau IW,Verbeek W,Heidel FH,Werner M,Kreipe H,Teleanu V,Benner A,Döhner H,Grießhammer M,Döhner K

    更新日期：2017-04-01 00:00:00

  • Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.

    abstract：:Kinase inhibitors block proliferative signals in BCR-ABL1+ leukemic cells, but their capacity to induce apoptosis is poorly understood. Initial studies suggested that very brief exposure to kinase inhibitors was sufficient to induce apoptosis in chronic myeloid leukemia (CML) cells. However, flaws in this experimental...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.156

    authors： Schafranek L,Nievergall E,Powell JA,Hiwase DK,Leclercq T,Hughes TP,White DL

    更新日期：2015-01-01 00:00:00

  • Mesenchymal stromal cells in the antimicrobial host response of hematopoietic stem cell recipients with graft-versus-host disease--friends or foes?

    abstract：:Mesenchymal stromal cells (MSCs) are multipotent cells, which exhibit broad immunosuppressive activities. Moreover, they may be administered irrespectively of human leukocyte antigen (HLA) compatibility, without inducing life-threatening immunological reactions, as they express no HLA class II and limited HLA class I ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2014.127

    authors： Balan A,Lucchini G,Schmidt S,Schneider A,Tramsen L,Kuçi S,Meisel R,Bader P,Lehrnbecher T

    更新日期：2014-10-01 00:00:00

  • Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

    abstract：:Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal i...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/sj.leu.2405087

    authors： San-Miguel JF,Richardson PG,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Bladé J,Boccadoro M,Cavenagh JD,Neuwirth R,Boral AL,Esseltine DL,Anderson KC

    更新日期：2008-04-01 00:00:00

  • Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.

    abstract：:P38α/β has been described as a tumor-suppressor controlling cell cycle checkpoints and senescence in epithelial malignancies. However, p38α/β also regulates other cellular processes. Here, we describe a role of p38α/β as a regulator of acute lymphoblastic leukemia (ALL) proliferation and survival in experimental ALL m...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2015.153

    authors： Alsadeq A,Strube S,Krause S,Carlet M,Jeremias I,Vokuhl C,Loges S,Aguirre-Ghiso JA,Trauzold A,Cario G,Stanulla M,Schrappe M,Schewe DM

    更新日期：2015-12-01 00:00:00

  • STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK/T-cell lymphoma.

    abstract：:Nasal-type natural killer (NK) cell lymphoma is an infrequent aggressive malignant disease with very poor prognosis. We aimed to explore the possible role of the transcription factor STAT3 in the pathophysiology of this malignancy, as it was involved in oncogenesis and chemoresistance. For this, we established and cha...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2009.91

    authors： Coppo P,Gouilleux-Gruart V,Huang Y,Bouhlal H,Bouamar H,Bouchet S,Perrot C,Vieillard V,Dartigues P,Gaulard P,Agbalika F,Douay L,Lassoued K,Gorin NC

    更新日期：2009-09-01 00:00:00

  • Molecular remission as a therapeutic objective in acute promyelocytic leukemia.

    abstract：:Acute promyelocytic leukemia (APL) is a subtype of acute leukemia characterized by a unique t(15;17) translocation generating the PML/RARA fusion gene and hybrid oncoprotein. Besides its critical role in leukemogenesis, this genetic aberration serves as a disease-specific biomarker for rapid diagnosis and monitoring o...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/s41375-018-0219-5

    authors： Cicconi L,Fenaux P,Kantarjian H,Tallman M,Sanz MA,Lo-Coco F

    更新日期：2018-08-01 00:00:00

  • Chromosomal instability and radiosensitivity in myelodysplastic syndrome cells.

    abstract：:Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells. To investigate whether chromosomal instability and/or DNA repair defects are involved in the development of MDS, we measured the micronucleus (MN) frequency in peripheral blood lymphocytes exposed to various doses of X-rays, using a cytok...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402703

    authors： Kuramoto K,Ban S,Oda K,Tanaka H,Kimura A,Suzuki G

    更新日期：2002-11-01 00:00:00

  • Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis.

    abstract：:The AML1 (RUNX1)-MTG8 (ETO) fusion transcription factor generated by the t(8;21) translocation is believed to deregulate the expression of genes that are crucial for normal differentiation and proliferation of hematopoietic progenitors, resulting in acute myelogenous leukemia. To elucidate the role of AML1-MTG8 in leu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402465

    authors： Shimada H,Ichikawa H,Ohki M

    更新日期：2002-05-01 00:00:00

  • Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.

    abstract：:Allogeneic haemopoietic cell transplant (allo-HCT) may be curative in acute myeloid leukaemia (AML) in second complete remission (CR2) but the impact of reduced intensity (RIC) versus myeloablative conditioning (MAC) is uncertain. The Acute Leukaemia Working Party of the European Society for Blood and Bone Marrow Tran...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0527-4

    authors： Gilleece MH,Labopin M,Savani BN,Yakoub-Agha I,Socié G,Gedde-Dahl T,Blaise D,Byrne JL,Craddock C,Cornelissen JJ,Arcese W,Forcade E,Crawley C,Polge E,Mohty M,Nagler A

    更新日期：2020-01-01 00:00:00

  • A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.

    abstract：:A phase III clinical trial was developed to test whether the addition of etoposide to a high-dose cytosine arabinoside regimen would improve the remission rate, duration of remission, and survival in relapsed and refractory patients with acute myelogenous leukemia. One hundred and thirty-one patients stratified by age...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Vogler WR,McCarley DL,Stagg M,Bartolucci AA,Moore J,Martelo O,Omura GA

    更新日期：1994-11-01 00:00:00

  • Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

    abstract：:Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to therapy in chronic myeloid leukaemia (CML). We wanted to determine in what circumstances additional clinically relevant information was provided by simultane...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404139

    authors： Ross DM,Branford S,Moore S,Hughes TP

    更新日期：2006-04-01 00:00:00

  • Acquisition of the Ph chromosome and BCR-ABL fusion product in AML-M2 and t(8;21) leukemia: cytogenetic and FISH evidence for a late event.

    abstract：:A patient with the M2 subtype of AML who had a 45,X,-X,t(8;21) karyotype at diagnosis was found to have the Ph chromosome in one out of 37 evaluated cells 18 months after the initial diagnosis. Interphase FISH studies utilizing a BCR-ABL dual-color probe did not detect a fusion product 4 months prior to the appearance...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2400974

    authors： Najfeld V,Geller M,Troy K,Scalise A

    更新日期：1998-04-01 00:00:00

  • The impact of differential binding of wild-type RARalpha, PML-, PLZF- and NPM-RARalpha fusion proteins towards transcriptional co-activator, RIP-140, on retinoic acid responses in acute promyelocytic leukemia.

    abstract：:Retinoic acid receptor (RA) heterodimer (RAR/RXR) activities have been shown to be repressed by transcriptional co-repressor, SMRT/N-CoR, in the absence of the ligand while upon all-trans retionic acid (ATRA) treatment, SMRT/N-CoR is dissociated from RARalpha leading to gene expression by the recruitment of transcript...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401643

    authors： So CW,Dong S,So CK,Cheng GX,Huang QH,Chen SJ,Chan LC

    更新日期：2000-01-01 00:00:00

  • Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial.

    abstract：:PTEN gene inactivation by mutation or deletion is common in pediatric T-cell acute lymphoblastic leukemia (T-ALL), but the impact on outcome is unclear, particularly in patients with NOTCH1/FBXW7 mutations. We screened samples from 145 patients treated on the MRC UKALL2003 trial for PTEN mutations using heteroduplex a...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2015.206

    authors： Jenkinson S,Kirkwood AA,Goulden N,Vora A,Linch DC,Gale RE

    更新日期：2016-01-01 00:00:00

  • Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1.

    abstract：:Epigenetic deregulation is involved in acute myeloid leukemia (AML) pathogenesis and epigenetic targeting drugs are in clinical trial. Since the first results with histone-deacetylase inhibitors in AML are controversial, novel single and combined treatments need to be explored. It is tempting to combine chromatin-targ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.271

    authors： Chaib H,Nebbioso A,Prebet T,Castellano R,Garbit S,Restouin A,Vey N,Altucci L,Collette Y

    更新日期：2012-04-01 00:00:00

  • Essential thrombocythemia--clinical features, therapy and follow-up of 12 cases.

    abstract：:The authors analyzed twelve patients with symptomatic essential throthrombocythemia (E.T.) diagnosed from 1983 to 1991. Haemorrhagic and thrombotic phenomena were the main presenting features. Treatment consisted mostly of alpha-interferon (IFN-alpha 2b) subcutaneously in dosage ranging from 3 to 5 MU/m2 and hydroxyur...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Lopes E,Ribeiro MM,Silva MJ,Gandra M,Principe F,Granato C

    更新日期：1992-01-01 00:00:00

  • γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia.

    abstract：:Human cytomegalovirus (CMV) infections and relapse of disease remain major problems after allogeneic stem cell transplantation (allo-SCT), in particular in combination with CMV-negative donors or cordblood transplantations. Recent data suggest a paradoxical association between CMV reactivation after allo-SCT and reduc...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.374

    authors： Scheper W,van Dorp S,Kersting S,Pietersma F,Lindemans C,Hol S,Heijhuurs S,Sebestyen Z,Gründer C,Marcu-Malina V,Marchant A,Donner C,Plachter B,Vermijlen D,van Baarle D,Kuball J

    更新日期：2013-06-01 00:00:00

  • Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation.

    abstract：:Both conventional chimerism analysis (CCA) and lineage-specific chimerism analysis (LCA) have potential pitfalls as diagnostic means for the detection of minimal residual disease after allogeneic hematopoietic cell transplantation (aHCT). Therefore, the present study examines the results of both methods in order to de...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403719

    authors： Zeiser R,Spyridonidis A,Wäsch R,Ihorst G,Grüllich C,Bertz H,Finke J

    更新日期：2005-05-01 00:00:00

  • The benzene metabolite, hydroquinone, induces dose-dependent hypoploidy in a human cell line.

    abstract：:Chronic exposure to high concentrations of benzene can result in the development of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving high frequency of loss of all or part of chromosomes 5 and/o...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400763

    authors： Stillman WS,Varella-Garcia M,Gruntmeir JJ,Irons RD

    更新日期：1997-09-01 00:00:00

  • Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

    abstract：:In a European BIOMED-2 collaborative study, multiplex PCR assays have successfully been developed and standardized for the detection of clonally rearranged immunoglobulin (Ig) and T-cell receptor (TCR) genes and the chromosome aberrations t(11;14) and t(14;18). This has resulted in 107 different primers in only 18 mul...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,评审

    doi：10.1038/sj.leu.2403202

    authors： van Dongen JJ,Langerak AW,Brüggemann M,Evans PA,Hummel M,Lavender FL,Delabesse E,Davi F,Schuuring E,García-Sanz R,van Krieken JH,Droese J,González D,Bastard C,White HE,Spaargaren M,González M,Parreira A,Smith JL,Mor

    更新日期：2003-12-01 00:00:00

  • Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

    abstract：:The concept of applying all active therapeutic agents in Total Therapy (TT) clinical trials for newly diagnosed multiple myeloma was pursued with the intent of developing curative treatment. The results of TT1 (n=231), TT2 (n=668) without or with thalidomide and TT3 with added bortezomib (n=303) have been reported. An...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.160

    authors： Usmani SZ,Crowley J,Hoering A,Mitchell A,Waheed S,Nair B,AlSayed Y,Vanrhee F,Barlogie B

    更新日期：2013-01-01 00:00:00